Published in Clin Endocrinol (Oxf) on December 01, 1999
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol (2001) 5.28
Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood (2001) 3.66
The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol (2007) 3.51
Guidelines for acromegaly management: an update. J Clin Endocrinol Metab (2009) 2.96
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Synthesis of a cortisol-biotin conjugate and evaluation as a tracer in an immunoassay for salivary cortisol measurement. J Steroid Biochem Mol Biol (1992) 2.56
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) (2000) 2.19
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab (2010) 2.16
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab (1997) 2.14
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab (2001) 2.13
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol (2009) 2.13
Impairment of GH secretion in adults with primary empty sella. J Endocrinol Invest (2002) 2.09
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Methodology-dependent variation in documentation of outcome predictors in out-of-hospital cardiac arrest. Acad Emerg Med (1995) 2.01
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int (2013) 2.00
Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab (2000) 1.99
Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase. J Clin Microbiol (2001) 1.92
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia (2004) 1.84
Effectiveness of bystander cardiopulmonary resuscitation and survival following out-of-hospital cardiac arrest. JAMA (1995) 1.83
Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab (2000) 1.83
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol (2007) 1.83
Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab (1993) 1.80
High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol (2001) 1.74
A d.c. magnetic metamaterial. Nat Mater (2008) 1.69
Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab (1994) 1.69
Fistuloclysis can successfully replace parenteral feeding in the nutritional support of patients with enterocutaneous fistula. Br J Surg (2004) 1.66
Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest (2002) 1.65
Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ) (2005) 1.63
Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab (1999) 1.62
High prevalence of reflux symptoms in duodenal ulcer patients who develop gastro-oesophageal reflux disease after curing Helicobacter pylori infection. Dig Liver Dis (2001) 1.61
Low dose (1 microg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison's disease. Clin Endocrinol (Oxf) (2000) 1.60
Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab (1998) 1.58
Percutaneous computed tomography-guided ethanol injection in aldosterone-producing adrenocortical adenoma. Eur J Endocrinol (1995) 1.56
The molecular basis of alloreactivity. Immunol Today (1990) 1.56
Detection of doping with human growth hormone. Lancet (1999) 1.55
Salivary cortisol levels throughout childhood and adolescence: relation with age, pubertal stage, and weight. Pediatr Res (1995) 1.54
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
Accuracy of a new monoclonal stool antigen test in post-eradication assessment of Helicobacter pylori infection: comparison with the polyclonal stool antigen test and urea breath test. Dig Liver Dis (2005) 1.52
Prior radiation and chemotherapy increase the risk of life-threatening complications after insertion of metallic stents for esophagogastric malignancy. Gastrointest Endosc (1996) 1.52
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest (2006) 1.52
Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab (2001) 1.51
Applicability of the Greulich and Pyle skeletal age standards to black and white children of today. Am J Dis Child (1993) 1.51
Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab (2000) 1.49
Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine (2013) 1.48
Guidelines for acromegaly management. J Clin Endocrinol Metab (2002) 1.48
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol (Oxf) (1999) 1.48
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol (Oxf) (2009) 1.46
Spinal deformity index in patients with type 2 diabetes. Endocrine (2012) 1.45
Circulating ghrelin levels in the newborn are positively associated with gestational age. Clin Endocrinol (Oxf) (2004) 1.44
Dental caries and enamel defects in very low birth weight adolescents. Caries Res (2010) 1.44
Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass. Eur J Endocrinol (2001) 1.44
Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest (2000) 1.44
Human lymphocyte-activating properties of a purified polysaccharide from Candida albicans: B and T cell cooperation in the mitogenic response. J Immunol (1980) 1.44
Identification and antimicrobial susceptibility testing of clinical isolates of nonfermenting gram-negative bacteria by the Phoenix Automated Microbiology System. New Microbiol (2002) 1.43
Peptide analogues as a strategy to induce tolerance in T cells with indirect allospecificity. Transplantation (2000) 1.43
Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol (1990) 1.43
Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J (1997) 1.43
Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril (1996) 1.43
Speculations on the specificity of suppression. Immunol Today (1989) 1.43
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. J Endocrinol Invest (2003) 1.43
NOD2/CARD15 in healthy relatives of IBD patients. Eur Rev Med Pharmacol Sci (2006) 1.41
Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab (2004) 1.40
Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns? J Endocrinol Invest (2002) 1.40
CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol (1995) 1.40
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) (2000) 1.40
Different dysregulations in adrenal steroid biosynthesis as a prevalent cause of hyperandrogenism in women from southern Italy. Fertil Steril (1997) 1.40
The orbital veins. Am J Ophthalmol (1967) 1.39
[Effectiveness of and tolerability to oral desmopressin in the treatment of central diabetes insipidus]. Minerva Med (1992) 1.39
Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol (1996) 1.39
Cardiac arrest witnessed by prehospital personnel: intersystem variation in initial rhythm as a basis for a proposed extension of the Utstein recommendations. Ann Emerg Med (1997) 1.39
Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection. Am J Trop Med Hyg (1988) 1.38
ACROSTUDY: the Italian experience. Endocrine (2014) 1.38
Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol (2009) 1.37
Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab (2001) 1.37
Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab (1999) 1.36
Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg (2002) 1.35
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab (2001) 1.32
Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Eur J Hum Genet (1999) 1.32
Anergic T cells inhibit the antigen-presenting function of dendritic cells. J Immunol (2000) 1.32
Generation of suppressor cells in the response of human lymphocytes to a polysaccharide from Candida albicans. J Immunol (1981) 1.31
Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology (1996) 1.28
Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab (2004) 1.28